Sagimet Biosciences Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Sagimet Biosciences Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $96.00K, a 9500.00% increase year-over-year.
- Sagimet Biosciences Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $274.00K.
- Sagimet Biosciences Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $1.00K.
- Sagimet Biosciences Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $114.00K.
- Sagimet Biosciences Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $275.00K, a 141.23% increase from fiscal 2024.
- Sagimet Biosciences Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $114.00K, a 1800.00% increase from fiscal 2023.
- Sagimet Biosciences Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $6.00K, a 50.00% decline from fiscal 2022.
- Sagimet Biosciences Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $12.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $96.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $275.00K 10-K · filed 2026-03-11 | |
| 2025-09-30 | $274.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $1.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $114.00K 10-K · filed 2026-03-11 | |
| 2024-03-31 | $114.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $6.00K 10-K · filed 2025-03-12 | |
| 2023-09-30 | $6.00K 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $12.00K 10-K · filed 2024-03-25 | |
| 2022-03-31 | $12.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |